Candel Therapeutics, Inc. financial data

Symbol
CADL on Nasdaq
Location
117 Kendrick Street, Suite 450, Needham, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 184 % -76.8%
Debt-to-equity -1.95K % -2547%
Return On Equity 3.21K %
Return On Assets -173 % -244%
Operating Margin -27.8K % -35%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 32.5M shares +12.3%
Common Stock, Shares, Outstanding 32.1M shares +11.1%
Entity Public Float 28.2M USD -61%
Common Stock, Value, Issued 322K USD +11%
Weighted Average Number of Shares Outstanding, Basic 32M shares +10.7%
Weighted Average Number of Shares Outstanding, Diluted 32M shares +10.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 125K USD 0%
Research and Development Expense 21.8M USD -2.09%
General and Administrative Expense 13.8M USD -1.39%
Operating Income (Loss) -35.5M USD +1.73%
Nonoperating Income (Expense) -16.7M USD -492%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -52.2M USD -63.5%
Earnings Per Share, Basic -1.74 USD/shares -58.2%
Earnings Per Share, Diluted -1.74 USD/shares -58.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 16.6M USD -61.5%
Assets, Current 18.1M USD -59.9%
Property, Plant and Equipment, Net 2.48M USD -32.6%
Operating Lease, Right-of-Use Asset 614K USD -30.1%
Assets 21.5M USD -57%
Accounts Payable, Current 296K USD +18.4%
Employee-related Liabilities, Current 2.34M USD +20.6%
Accrued Liabilities, Current 4.57M USD +33.2%
Liabilities, Current 15.3M USD +47.8%
Operating Lease, Liability, Noncurrent 555K USD -49.9%
Liabilities 36.8M USD +36%
Retained Earnings (Accumulated Deficit) -178M USD -41.5%
Stockholders' Equity Attributable to Parent -15.3M USD -166%
Liabilities and Equity 21.5M USD -57%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.44M USD +22%
Net Cash Provided by (Used in) Financing Activities -1.26M USD
Net Cash Provided by (Used in) Investing Activities -7K USD -137%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 32.2M shares +11%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -9.7M USD +10.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 16.8M USD -61.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 549K USD +9.8%
Deferred Tax Assets, Valuation Allowance 40.5M USD +39%
Deferred Tax Assets, Gross 41M USD +36.9%
Operating Lease, Liability 1.11M USD -31.1%
Depreciation 981K USD 0%
Payments to Acquire Property, Plant, and Equipment 7K USD -94.9%
Lessee, Operating Lease, Liability, to be Paid 1.18M USD -33.5%
Property, Plant and Equipment, Gross 5.31M USD -3.72%
Operating Lease, Liability, Current 552K USD +10.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 415K USD -32.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 613K USD +2.51%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 73K USD -56.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 415K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 23.1M USD +30.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 415K USD -32.3%
Operating Lease, Payments 587K USD +11%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 230K USD +39.4%
Deferred Tax Assets, Net of Valuation Allowance 501K USD -39.5%
Share-based Payment Arrangement, Expense 5.01M USD +79.7%
Interest Expense 2.37M USD -27.2%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%